[PDF][PDF] Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer
…, M Jimenez, K Kouvelakis, R Ranftl, R Begum, I Rana… - Cancer cell, 2019 - cell.com
Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against
a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the …
a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the …
MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer
…, MA Bali, R Shaikh, T Jones, R Begum, I Rana… - Clinical Cancer …, 2020 - AACR
Purpose: Response to preoperative chemo-radiotherapy (CRT) varies. We assessed
whether circulating tumor DNA (ctDNA) might be an early indicator of tumor response or …
whether circulating tumor DNA (ctDNA) might be an early indicator of tumor response or …
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study
…, S Marchetti, A Lampis, MD Damavandi, H Lote, I Rana… - Gut, 2018 - gut.bmj.com
Objective Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC).
Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns …
Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns …
Ultra-sensitive mutation detection and genome-wide DNA copy number reconstruction by error-corrected circulating tumor DNA sequencing
…, A Patel, A Wotherspoon, A Okachi, I Rana… - Clinical …, 2018 - academic.oup.com
BACKGROUND Circulating free DNA sequencing (cfDNA-Seq) can portray cancer genome
landscapes, but highly sensitive and specific technologies are necessary to accurately …
landscapes, but highly sensitive and specific technologies are necessary to accurately …
miR-31-3p expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective phase II PROSPECT-C trial
…, N Khan, N Fotiadis, M Rugge, R Begum, I Rana… - Clinical Cancer …, 2019 - AACR
Purpose: Anti-EGFR mAbs are effective in the treatment of metastatic colorectal cancer (mCRC)
patients. RAS status and tumor location (sidedness) are predictive markers of patients' …
patients. RAS status and tumor location (sidedness) are predictive markers of patients' …
[HTML][HTML] ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III …
S Slater, A Bryant, HC Chen, R Begum, I Rana… - BMC cancer, 2023 - Springer
Background Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is
emerging as a biomarker to predict recurrence in patients with curatively treated early stage …
emerging as a biomarker to predict recurrence in patients with curatively treated early stage …
SARS-CoV-2 vaccine immunogenicity in patients with gastrointestinal cancer receiving systemic anti-cancer therapy
…, S Kidd, S Cromarty, R Begum, I Rana… - The …, 2023 - academic.oup.com
Introduction Patients with gastrointestinal (GI) cancers have an increased risk of serious
complications and death from SARS-CoV-2 infection. The immunogenicity of vaccines in …
complications and death from SARS-CoV-2 infection. The immunogenicity of vaccines in …
[PDF][PDF] Perioperative FLOT plus anti-PD-L1 avelumab (FLOT-A) in resectable oesophagogastric adenocarcinoma (OGA): interim safety analysis results from the …
…, M Moneypenny, R Begum, K von Loga, I Rana… - J Clin …, 2021 - researchgate.net
Perioperative FLOT plus anti-PD-L1 Avelumab (FLOT-A) in resectable oesophagogastric
adenocarcinoma (OGA): Interim safety analysi Page 1 Perioperative FLOT plus anti-PD-L1 …
adenocarcinoma (OGA): Interim safety analysi Page 1 Perioperative FLOT plus anti-PD-L1 …
[HTML][HTML] Detecting and tracking circulating tumour DNA copy number profiles during first line chemotherapy in oesophagogastric adenocarcinoma
…, S Mansukhani, B Griffiths, SY Moorcraft, I Rana… - Cancers, 2019 - mdpi.com
DNA somatic copy number aberrations (SCNAs) are key drivers in oesophagogastric
adenocarcinoma (OGA). Whether minimally invasive SCNA analysis of circulating tumour (ct)DNA …
adenocarcinoma (OGA). Whether minimally invasive SCNA analysis of circulating tumour (ct)DNA …
Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA).
…, R Lazaro-Alcausi, R Crux, V Borja, R Begum, I Rana… - 2023 - ascopubs.org
446 Background: ICONIC evaluated 4+4 cycles of FLOT-A (2-weekly standard FLOT with
10mg/kg of the anti-PDL1 antibody avelumab) for perioperative treatment of early-stage OGA. …
10mg/kg of the anti-PDL1 antibody avelumab) for perioperative treatment of early-stage OGA. …